Those who have followed the work of the Council on Pharmacy and Chemistry and of the Association Laboratory in their efforts to safeguard the interests of the medical profession and the public will be interested in the report on bismuth iodo-resorcin sulphonate that appears in this issue. The case there presented is not one in which a manufacturer has deliberately misrepresented his product; rather it is a case of carelessness. In submitting its product to the Council, the firm made statements which it could, and should, have known were not true. The question arises: if a firm is careless enough to make incorrect statements to the Council on Pharmacy and Chemistry which it knows will critically examine the claims, what degree of “carelessness” may be expected when the products are exploited direct to physicians? The answer, which must occur to any thinking person, is such as to make one pause.
CARELESSNESS VS. MISREPRESENTATION. JAMA. 2011;305(6):626. doi:10.1001/jama.2010.1920